Back to top
more

Xenon Pharmaceuticals (XENE)

(Delayed Data from NSDQ)

$40.50 USD

40.50
320,772

+0.40 (1.00%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $40.53 +0.03 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus

by Zacks Equity Research

Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.

Here's Why You Should Add Xenon (XENE) to Your Portfolio Now

by Zacks Equity Research

Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.

Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study

by Zacks Equity Research

Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.

Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study

by Zacks Equity Research

Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.

Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -4.35% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 6.90% and 86.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Q2 Earnings Lag Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -1.61% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline

by Zacks Equity Research

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Xenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 1.72% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -12.25% and 91.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of 10.11% and 11.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 7.89% and 4.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 38.46% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -16.16% and 19.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -21.28% and 11.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?